



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number:

0 449 186 A2

EUROPEAN PATENT APPLICATION

(12)

(21) Application number: 91104711.6

(22) Date of filing: 26.03.91

(51) Int. Cl. 5: **C07D 211/22, C07D 211/32,
C07D 401/06, C07D 211/34,
C07D 407/06, C07D 409/06**

(30) Priority: 28.03.90 US 500573

(43) Date of publication of application:
02.10.91 Bulletin 91/40

(64) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: **THE DU PONT MERCK
PHARMACEUTICAL COMPANY
1007 Market Street
Wilmington, Delaware 19898(US)**

(72) Inventor: **Cain, Gary Avonn
8 Wayne Drive
Wilmington, Delaware 19809(US)
Inventor: Gilligan, Paul Joseph
773 Montclair Drive
Claymont, Delaware 19703(US)
Inventor: Tam, Sang William
443 Stella Drive
Hockessin, Delaware 19707(US)**

(74) Representative: **von Kreisler, Alek,
Dipl.-Chem. et al
Patentanwälte Von Kreisler-Selting-Werner,
Delchmannhaus am Hauptbahnhof
W-5000 Köln 1(DE)**

(54) **N-alkyl piperidine derivatives as psychotropic drugs.**

(57) There are provided N-alkyl piperidine derivatives which are selective sigma receptor antagonists. These compounds and pharmaceutical compositions containing them are useful for treating physiological or drug induced psychosis or dyskinesia in a mammal.

EP 0 449 186 A2